- German DAX trades lower today
- Halozyme Therapeutics Inc. has made a non-binding offer to acquire German drug developer Evotec SE
- RWE AG has announced a €1.5 billion ($1.6 billion) share buyback program
General market situation:
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appEuropean markets are showing mixed performance, with the Spanish SPA35 leading gains at 0.44%, while the Dutch NED25 is marginally up by 0.06%. The Italian ITA40 and French FRA40 are slightly lower, down 0.06% and 0.11% respectively. The UK's UK100 has declined 0.18%, while the Austrian AUT20 is down 0.23%. The broader EU50 and German DE40 are both in negative territory, falling 0.31% and 0.34%. The Swiss SUI20 and Polish W20 show the largest declines among European indices, dropping 0.77% and 0.93% respectively.
Dax Returns by Sector. Source: Bloomberg Financial LP
The German DAX is down 0.55% overall, with most sectors trading in negative territory. Consumer Discretionary is the only notable gainer, up 0.20%. Information Technology is showing the largest decline (-1.50%), followed by Health Care (-1.07%). The Industrials sector, a significant component of the DAX, is down 0.49%. Other notable declines include Materials (-0.14%), Utilities (-0.17%), Financials (-0.24%), and Communication Services (-0.29%). Real Estate also shows weakness, declining 0.47%. The visualization shows a predominantly bearish sentiment across sectors, with 9 out of 10 sectors trading lower.
Volatility is currently observed in the broader European market. Source: xStation
The German DE40 Index is trading above the 38.2% Fibonacci retracement level but below the 50-day SMA. For bears, the 50% Fibonacci retracement level is the first test, having previously acted as support. If breached, the 100-day SMA and 61.8% Fibonacci retracement level could be retested. For bulls, key resistance lies at the 23.6% Fibonacci retracement level. RSI shows bearish divergence with lower highs and lows, while MACD indicates negative sentiment. Source: xStation
News
- EON (EOAN.DE) has increased its investments by 20% to €4.7 billion ($5 billion) in the first nine months of 2023, primarily focusing on grid expansion and modernization. Despite a 14% drop in adjusted EBITDA to €6.7 billion, the company maintains its full-year profit guidance of €8.8-9 billion. The utility faces uncertainty regarding a pending court case on grid returns.
- RWE AG (RWE.DE) has announced a €1.5 billion ($1.6 billion) share buyback program amid concerns over U.S. offshore wind investments following Trump's election and slower European hydrogen development. The company's shares surged over 8% on the news, marking their best performance in two years. RWE also raised its 2024 earnings outlook, now targeting the midpoint of its adjusted EBITDA range of €5.2-5.8 billion.
- Siemens AG (SIE.DE) reached an all-time high stock price after forecasting up to 7% revenue growth for the coming year, driven by strong demand from data centers for its transformers and grid technology. The company announced a record €9 billion net income for fiscal 2024 and increased its dividend by 11% to €5.20 per share. CEO Roland Busch also confirmed plans to proceed with the €10 billion acquisition of Altair Engineering Inc.
- Halozyme Therapeutics Inc. (HALO.US) has made a non-binding offer to acquire German drug developer Evotec SE (EVT.DE) for €11 per share, valuing the company at €2 billion ($2.1 billion). The offer represents a 27% premium to Evotec's closing price. The news comes as Evotec works to rebuild investor trust following the departure of its previous CEO Werner Lanthaler and disclosure of delayed stock trade reporting.
Other news coming from individual DAX index companies. Source: Bloomberg Financial LP
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
